Background
Mannose-binding lectin (MBL; mannan-binding protein or lectin) is involved in innate immune defense, is produced largely by hepatocytes, and is encoded by
MBL2 (chromosome 10q21.1). MBL is an oligomer that binds repeating sugar residues (especially D-mannose and
N-acetyl glucosamine oligosaccharides) expressed on the surfaces of diverse microorganisms [
1]. MBL promotes killing of microorganisms by complement activation via the lectin pathway and by opsonization [
2]. Three common
MBL2 exon 1 mutations (sometimes designated as B, C, and D) encode unstable MBL polypeptides with subnormal molecular weight, blood levels, oligimerization, ligand binding, and complement activation [
3,
4] and limited acute-phase responses to severe infection [
5].
MBL2 promoter region haplotypes account for variability of blood MBL levels across race/ethnicity groups unexplained by exon 1 alleles [
6]. In young male Finnish military recruits with or without asthma, MBL levels below the median were associated with significantly increased odds of respiratory tract infection, after adjustment for asthma status [
7].
Immunoglobulin (Ig) G (IgG), synthesized by plasma cells, is the predominant of five classes of Igs in humans. Although the four IgG subclasses share ~ 90% amino acid identity, each subclass has different antigen binding, immune complex formation, complement activation, and half-life [
8]. IgG subclass deficiency (IgGSD) in adults is characterized by: levels of IgG1–3 subclasses more than two standard deviations (SD) below the population mean; frequent or severe respiratory tract infection; suboptimal IgG responses to pneumococcal polysaccharides; and increased prevalence of autoimmune conditions [
9,
10]. A study of Dutch adults with recurrent respiratory tract infection revealed no significant clinical differences between subjects with or without
MBL2 genotypes that predict low MBL production after subjects with subnormal serum Ig levels or suboptimal responses to 23-valent pneumococcal polysaccharide vaccine were excluded from the analyses [
11].
We sought to determine associations of serum MBL levels with other characteristics of 219 consecutive unrelated non-Hispanic white adults at diagnosis of IgGSD in a retrospective study. We computed the correlation of first and second serum mannose-binding levels expressed as natural logarithms (ln) in a patient subgroup. We compared these characteristics of all patients with and without MBL ≤50 ng/mL: age at diagnosis; sex; body mass index (BMI); upper and lower respiratory tract infection; diabetes; autoimmune condition(s); atopy; other allergy; corticosteroid therapy; and subnormal serum levels of IgG subclasses, IgA, and IgM (dichotomous variables). We also performed logistic regression on MBL ≤50 ng/mL (dichotomous). We discuss characteristics of the present cohort and compare them with those of Caucasian white adults unselected for IgGSD who were evaluated for prevalence of low MBL levels (or corresponding MBL2 genotypes) and risk of respiratory tract infection.
Discussion
Serum MBL ≤50 ng/mL occurred in 16.4% of the present 219 patients. Twelve of 100 healthy Danish blood donors (12.0%) had plasma MBL < 50 ng/mL [
17]. Twenty-seven of 164 healthy white Spanish adults (16.5%) had
MBL2 genotypes that predicted low MBL levels (mean serum MBL 62 ± 9 (SD) ng/mL) [
18]. Thus, the proportion of the present patients with MBL ≤50 ng/mL is similar to proportions of control adults in two healthy western European cohorts with low MBL levels or
MBL2 genotypes that predict low MBL levels. First and second MBL levels in 14 of the present patients were similar, consistent with a report that variation of MBL levels in healthy adults over time is not significant [
19]. General clinical and laboratory characteristics of the present patients with MBL ≤50 ng/mL and those with MBL > 50 ng/mL did not differ significantly.
MBL ≤50 ng/mL was not significantly associated with age at IgGSD diagnosis in the present patients (mean age 51 y). In common variable immunodeficiency, the mean age of disease onset was significantly lower in patients with
MBL2 exon 1 mutations and promoter haplotypes that predict low MBL production than in patients with wild-type
MBL2 alleles (15 y vs. 25 y, respectively) [
20].
MBL levels and BMI were inversely associated in a correlation analysis, although this association was not especially strong. Mean MBL levels of the present patients with BMI < 30.0 kg/m
2 and those with BMI ≥30.0 kg/m
2 did not differ significantly. BMI was not a significant predictor of MBL ≤50 ng/mL in a logistic regression. In a study of German adults not selected for IgGSD or frequent or severe respiratory tract infection, mean plasma MBL levels in severely obese and healthy, lean subjects did not differ significantly [
21]. In obese German and Swedish subjects, MBL levels did not change significantly after weight loss [
21,
22]. MBL mRNA is not expressed in adipose tissue [
22].
Mean/median MBL levels of the present men and women did not differ significantly. In healthy American military beneficiaries (83% Caucasians), the prevalence of serum MBL < 50 ng/mL was significantly lower in men than women (14% vs. 20%, respectively) and the prevalence of MBL > 2000 ng/mL was significantly higher in men than women (28% vs. 21%, respectively) [
23]. In a review of 84 studies, Falagas et al. concluded that males in all age groups develop respiratory tract infections (except sinusitis, otitis externa, and probably tonsillitis) more frequently than females, and that differences in sites of respiratory tract infection between males and females are probably influenced by diverse genetic, biochemical, anatomical, and socioeconomic factors [
24].
The prevalence of upper and lower respiratory tract infection was lower in the present patients with MBL ≤50 ng/mL than in patients with MBL > 50 ng/mL, but these differences were not statistically significant. In British adults with chronic obstructive pulmonary disease, those with
MBL2 genotypes that predicted low MBL levels had lower risk of infective exacerbations, greater lung microbiota diversity, and decreased airway inflammation [
25]. In adults with rheumatoid arthritis, estimated rates of verified upper respiratory tract infections per 100 patient-years did not differ significantly between those with serum MBL < 100 ng/mL and those with higher MBL levels [
26].
Lower respiratory tract infection was reported by 86% of the present patients with IgGSD, but we observed no significant relationships of MBL and lower respiratory tract infection. The frequencies of
MBL2 alleles and genotypes in Spanish white adults with community-acquired pneumonia and control subjects did not differ significantly, but
MBL2 genotypes that predicted low MBL levels were associated with significantly greater severity of illness and risk of death [
18]. In a case-control study of Spanish adults, there was no significant relationship of
MBL2 genotypes and pneumococcal community-acquired pneumonia (with or without bacteremia) [
27]. In British adults with chronic obstructive pulmonary disease, the risk of infective exacerbations was significantly lower in patients with
MBL2 genotypes that predicted low MBL levels [
25]. In Norwegian adults hospitalized for treatment of community-acquired pneumonia, 13% had serum MBL < 50 ng/mL and 34% had subnormal serum Ig levels, but MBL < 50 ng/mL was not associated with specific causative microorganisms, severity of illness, or short- or long-term outcomes [
28]. Taken together, these reports suggest that associations of low MBL levels and lower respiratory tract infection in cohorts of Caucasian adults unselected for subnormal total IgG or IgG subclasses vary according to specific infective microorganisms, the presence or absence of underlying lung disease, and serum Ig levels.
Mean MBL levels of the present patients with and without diabetes did not differ significantly. MBL ≤50 ng/mL (dichotomous) was associated with decreased odds of diabetes in a logistic regression. In a multivariable regression on MBL levels (continuous), there was a positive association with diabetes. Mean serum MBL levels were significantly higher in Danish adults with type 1 diabetes and normal urine albumin levels than in healthy age- and sex-matched control subjects [
29]. Mean serum MBL levels in Danish adults with type 2 diabetes and healthy blood donors did not differ significantly [
30]. Frequencies of
MBL2 genotypes were similar in Swedish adults with type 2 diabetes [
31] and subjects in the general European population [
17,
32].
Autoimmune condition(s), an aggregate variable in this study, was not significantly associated with MBL ≤50 ng/mL or MBL levels. In Czech adults with autoimmune thyroid disease and healthy Czech control subjects, the prevalence of
MBL2 polymorphisms did not differ significantly [
33]. In Danish adults with rheumatoid arthritis, the prevalence of undetectable serum MBL was significantly higher than that of control subjects (11% vs. 3%, respectively) [
34]. Among Australian adults with rheumatoid arthritis, serum MBL < 56 ng/mL was associated with a significantly increased risk of infection that required in-hospital management [
35]. In Finnish patients with primary Sjögren syndrome and control subjects, there was no significant difference in
MBL2 genotype or allele frequencies [
36]. In Dutch adults with systemic lupus erythematosus (77% Caucasian), functional MBL activity < 10% of normal was not associated with increased infection risk [
37]. In contrast, homozygosity for
MBL2 alleles that predicted low MBL levels was higher in Danish patients with systemic lupus erythematosus than in control subjects, and was associated with significantly greater infection risk [
38].
Atopy, defined as a dichotomous variable in this study, was not significantly associated with MBL ≤50 ng/mL or MBL levels. In Finnish adults with asthma and control subjects, there was no significant association of
MBL2 genotype and atopy (defined as a wheal reaction to one or more of 22 allergens applied by skin pricks) [
39].
MBL ≤50 ng/mL was not significantly associated with subnormal IgG subclasses, IgA, or IgM. In another study, five of 12 American adults with chronic rhinosinusitis and MBL < 100 ng/mL also had subnormal IgG subclass levels, including three with subnormal IgG3 [
40]. In contrast, MBL < 20 ng/mL in Finnish adults with IgA < 0.05 g/L, alone or in combination with subnormal IgG subclass levels, was not associated with increased risk of respiratory infection [
41].
Decreased IgG responses to 23-valent pneumococcal polysaccharide vaccination are common in adults with IgGSD [
10,
12,
42,
43]. In Dutch adults with recurrent respiratory tract infections who were unselected for total IgG or IgG subclass levels, responses to 23-valent pneumococcal polysaccharide vaccination were similar in subjects with or without functional MBL activity < 10% of normal [
11].
A strength of this study is that this sample size provides statistical power to estimate independent joint effects in multivariable models. Limitations of this study include lack of: control subjects; identification of microorganisms associated with infections; MBL2 genotyping; evaluation of lectin and opsonization pathways; and evaluation of 23-valent pneumococcal vaccination responses. Family studies and longitudinal follow-up of the present patients were beyond the scope of this study.